← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
RA Capital Nexus Fund, L.P.
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001780117
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 12
- Purchases · 24M
- 18
- Average purchase
- $11.0M
- Median purchase
- $1.8M
- Gross purchase value
- $198.9M
Companies: 89bio, Inc. | Artiva Biotherapeutics, Inc. | Climb Bio, Inc. | Sionna Therapeutics, Inc. | Tyra Biosciences, Inc.
18 SEC accession(s) · 18 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-31 | Artiva Biotherapeutics, Inc. | ARTV | Director | $455.7K | Open filing |
| 2026-07-28 | Artiva Biotherapeutics, Inc. | ARTV | Director | $412.8K | Open filing |
| 2026-07-23 | Artiva Biotherapeutics, Inc. | ARTV | Director | $58.3K | Open filing |
| 2026-07-23 | Artiva Biotherapeutics, Inc. | ARTV | Director | $2.6M | Open filing |
| 2026-07-20 | Artiva Biotherapeutics, Inc. | ARTV | Director | $1.4M | Open filing |
| 2026-07-14 | Artiva Biotherapeutics, Inc. | ARTV | Director | $194.0K | Open filing |
| 2026-06-29 | Artiva Biotherapeutics, Inc. | ARTV | Director | $292.1K | Open filing |
| 2026-06-16 | Artiva Biotherapeutics, Inc. | ARTV | Director | $4.6M | Open filing |
| 2026-06-11 | Artiva Biotherapeutics, Inc. | ARTV | Director | $7.7M | Open filing |
| 2026-05-13 | Artiva Biotherapeutics, Inc. | ARTV | Director | $75.0M | Open filing |
| 2026-01-07 | Climb Bio, Inc. | CLYM | Director | $24.9K | Open filing |
| 2025-12-15 | Climb Bio, Inc. | CLYM | Director | $754.7K | Open filing |
| 2025-06-16 | Tyra Biosciences, Inc. | TYRA | Director | $1.7M | Open filing |
| 2025-06-11 | Tyra Biosciences, Inc. | TYRA | Director | $1.9M | Open filing |
| 2025-06-06 | Tyra Biosciences, Inc. | TYRA | Director | $11.8M | Open filing |
| 2025-02-10 | Sionna Therapeutics, Inc. | SION | Director | $20.2M | Open filing |
| 2025-02-03 | 89bio, Inc. | ETNB | Director | 10% Owner | $50.0M | Open filing |
| 2024-11-13 | Tyra Biosciences, Inc. | TYRA | Director | 10% Owner | $19.8M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 2/15
- Large purchase ≥ $100k
- 16/18
- Cluster buying · 15D
- 18/18
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.